Cremophor EL-36
Based on 1 Customer Validation
Cremophor EL-36 is a non-ionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). For example, Cremophor EL-36 can enhance the intracellular influx of Etoposide (HY-13629) without affecting drug efflux, and can dose-dependently increase the accumulation of VP-16 in lung adenocarcinoma cells (such as PC-14 and A549), significantly enhancing its cytotoxic effect.
For research use only. We do not sell to patients.
- CAS No.: 61791-12-6
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
The functions of Cremophor EL-36 include: 1) influencing pharmacokinetics by encapsulating drugs in micelles, altering drug distribution and clearance; 2) activating the complement system, triggering allergic reactions; and 3) binding to lipoproteins, interfering with lipid metabolism. Cremophor EL-36 increases drug solubility through micellization, while simultaneously mediating toxicity through complement activation and lipoprotein interactions. Cremophor EL-36 is a non-ionic surfactant-based drug sensitizer that does not depend on the MDR1 target. In drug solubilization experiments, the optimal ratio of Cremophor EL-36 to the drug is 10:1 (w/w), forming stable micelles (particle size <100 nm)[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 61791-12-6
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Cremophor EL-36]
-
Synonyms
Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
H2O : ≥ 100 mg/mL
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sparreboom A, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999 Apr 1;59(7):1454-7. [Content Brief]
[2]. Engblom P, et al. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis[J]. European Journal of Cancer, 1999, 35(2): 284-288. [Content Brief]
[3]. Watanabe T, et al. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs. 1996 Nov;7(8):825-32. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)